myelodysplastic syndromes (MDS) | Page 159 | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

Maria Baer, MD

Baer, Maria
Director, Hematologic Malignancies Program
University of Maryland Greenebaum Comprehensive Cancer Center

Maria Baer joined the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, Maryland in 2007 as director of hematologic malignancies and professor of medicine and molecular medicine, University of Maryland School of Medicine. She previously served as chief of the leukemia section at Roswell Park Cancer Institute and professor of medicine and associate professor of molecular pharmacology and cancer therapeutics at the University at Buffalo School of Medicine and Biomedical Sciences in Buffalo, New York.

Mikkael Sekeres, MD, MS

Nimer, Stephen
Physician Liaison in Hematology and Chief of the Division of Hematology in the Department of Medicine
Sylvester Comprehensive Cancer Center and University of Miami

Mikkael A. Sekeres, MD, MS has been Medical Advisory Board Co-Chair since 2004. He is currently the Physician Liaison in Hematology and Chief of the Division of Hematology at the Sylvester Comprehensive Center at the University. Previously, Dr. Sekeres was the professor of medicine, director of the leukemia program, and Vice Chair for

Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.

Author(s): 
Cechova H, Lassuthova P, Novakova L, Belickova M, Stemberkova R, Jencik J, Stankova M, Hrabakova P, Pegova K, Zizkova H, Cermak J.
Primary Author: 
Cechova H
Journal Title: 
Neoplasma
Original Publication Date: 
Jan 2012

Abstract

Bone Marrow Disease(s): 

Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes.

Author(s): 
Davidoff AJ
Primary Author: 
Davidoff AJ, Weiss Smith S, Baer MR, Ke X, Bierenbaum JM, He
Journal Title: 
Haematologica
Original Publication Date: 
Jan 2012

Patient and physician characteristics associated with use of erythropoiesis-stimulating agents in myelodysplastic syndrome patients have not yet been described. Myelodysplastic syndrome patients diagnosed from 2001 to 2005 were identified from the Surveillance

Bone Marrow Disease(s): 

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

Author(s): 
Sibon D, Cannas G, Baracco F, Prebet T, Vey N, Banos A, Besson C, Corm S, Blanc M, Slama B, Perrier H, Fenaux P, Wattel E; on the behalf of the Groupe Francophone des Myélodysplasies.
Primary Author: 
Sibon D
Journal Title: 
Br J Haematol
Original Publication Date: 
Dec 2011

Bone Marrow Disease(s): 

Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes

Author(s): 
Zhao ZG, Xu W, Yu HP, Fang BL, Wu SH, Li F, Li WM, Li QB, Chen ZC, Zou P.
Primary Author: 
Zhao ZG
Journal Title: 
Cancer Lett
Original Publication Date: 
Oct 2011

Mesenchymal

Bone Marrow Disease(s): 
Share with addtoany.com.